Clinical trial · Interventional
A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
An Open-labeled Phase I Clinical Trial Evaluating the Safety, Tolerability, Biodistribution Characteristics, Biological EEffects, and Initial Efficacy of VRT106 for Injection in the Treatment of Locally Advanced/Metastatic Solid Tumors by Intravenous Administration
NCT06826313CI-TRIAL-00092319recruitingPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
A Phase I Study of the Safety and Tolerability of VRT106 Administered Intravenously for Treatment of Patients With Locally Advanced or MetastaticSolid Tumors
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VRT106 | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- VRT106 for injection
- description
- VRT106 will be administered through IV drip
- interventionNames
- Biological: VRT106
Primary outcomes (1)
- measure
- Evaluate the safety and tolerability of escalating doses of VRT106 in Patients with advanced malignanttumors
- timeFrame
- About 2 years
- description
- To evaluate the safety and tolerability of VRT106 in patients with locally advanced/metastatic solid tumours and to explore the maximum tolerated dose (MTD)/multiple ascending dose (MAD)/optimal biologically active dose (OBD) and/or the recommended phase 2 dose (RP2D), which will provide a recommended dose for subsequent clinical trials.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects voluntarily participate in the clinical study; fully understand and be informed about the study and sign the ICF; and are willing to follow and have the ability to complete all trial procedures. 2. Males and females are aged at 18-75 years (including borderline values) at the time of signing the ICF, male or female. 3. Subjects are histologically or cytologically confirmed to be intolerable or refractory to the standard systemic treatment. 4. Subjects have at least one measurable lesion. 5. ECOG score of 0 to 28 days prior to first dose of IMP. 6. An expected survival time of ≥ 12 weeks. 7. Have sufficient organ function. 8. Female patients of childbearing potential with a negative serum pregnancy test within 7 days prior to first dose of study drug. 9. Subjects of childbearing potential (males and females) agree to use effective birth control with their partner from signing informed consent to at least 90 days after the last dose. Exclusion Criteria: 1. Subject has received any antitumor therapy within 4 weeks prior to the first dose of IMP. 2. Subject has previously received oncolytic virus or other gene drug therapy. 3. Subject has received treatment with other unlisted clinical investigational drugs/devices within 4 weeks prior to the first dose of IMP. 4. Subject is known to have an allergic reaction to any of the components of IMP. 5. Women who are breastfeeding.
References
Publications (0)
Data not yet available
No reference posted for this study.